Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2535573 | 0.84 | HTT (0.88) | HTTKMT2AMEN1TSHRLMNA | |
| SCHEMBL28780179 | 0.84 | KMT2A (0.70) | HTTKMT2AMEN1SCN9ALMNA | |
| SCHEMBL2540114 | 0.83 | HTT (0.90) | HTTKMT2AMEN1SCN9ATSHR | |
| SCHEMBL26559708 | 0.80 | HTT (0.61) | HTTKMT2AMEN1SCN9ATSHR | |
| SCHEMBL29944122 | 0.80 | KMT2A (0.63) | HTTKMT2AMEN1TSHRLMNA | |
| SCHEMBL13977436 | 0.79 | HTT (0.73) | HTTKMT2AMEN1SCN9ATSHR | |
| SCHEMBL16109104 | 0.78 | HTT (0.62) | HTTKMT2AMEN1SCN9ATSHR | |
| SCHEMBL10156660 | 0.77 | HPGD (0.67) | HTTKMT2AMEN1TSHRLMNA | |
| SCHEMBL10991053 | 0.76 | KMT2A (0.70) | HTTKMT2ATSHRLMNAHPGD | |
| SCHEMBL19766699 | 0.76 | HTT (0.90) | HTTKMT2ATSHRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | LABORATORIOS ALMIRALL, S.A. | 2007-10-11 | — | — | US | disclosed |
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | disclosed |
| US-7253171-B2 | Urea derivatives as integrin α4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-07 | — | — | US | disclosed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
| EP-1383750-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002057242-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | ITGA4, ITGB4, ITGA1 | HTT 4701/4885KMT2A 3371/4885MEN1 4288/4885 |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | ITGB4, ITGA4, ITGB7 | HTT 4657/4885KMT2A 4075/4885MEN1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.